Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of refractory T‐cell malignancies using gemcitabine

Treatment of refractory T‐cell malignancies using gemcitabine We have treated 10 patients with relapsed or refractory T‐cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28‐d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20–35%). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T‐cell haematological neoplasms. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png British Journal of Haematology Wiley

Treatment of refractory T‐cell malignancies using gemcitabine

Loading next page...
 
/lp/wiley/treatment-of-refractory-t-cell-malignancies-using-gemcitabine-a8GSwpfvoS

References (13)

Publisher
Wiley
Copyright
Copyright © 2001 Wiley Subscription Services
ISSN
0007-1048
eISSN
1365-2141
DOI
10.1046/j.1365-2141.2001.02743.x
Publisher site
See Article on Publisher Site

Abstract

We have treated 10 patients with relapsed or refractory T‐cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28‐d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20–35%). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T‐cell haematological neoplasms.

Journal

British Journal of HaematologyWiley

Published: Jan 1, 2001

Keywords: ; ;

There are no references for this article.